Q2 Earnings Forecast for SCTX Issued By HC Wainwright

Scribe Therapeutics Inc. (NASDAQ:SCTX) – Analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for shares of Scribe Therapeutics in a research report issued to clients and investors on Monday, August 31st. HC Wainwright analyst M. Kapoor expects that the company will earn ($6.20) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $60.00 price objective on the stock. HC Wainwright also issued estimates for Scribe Therapeutics’ Q3 2026 earnings at ($1.02) EPS, Q4 2026 earnings at ($1.05) EPS, FY2026 earnings at ($6.72) EPS, Q1 2027 earnings at ($1.10) EPS, Q2 2027 earnings at ($1.17) EPS, Q3 2027 earnings at ($1.28) EPS, Q4 2027 earnings at ($1.36) EPS and FY2027 earnings at ($4.90) EPS.

A number of other equities research analysts have also weighed in on the stock. Guggenheim assumed coverage on shares of Scribe Therapeutics in a report on Tuesday, August 18th. They issued a “buy” rating and a $50.00 target price on the stock. Leerink Partners began coverage on Scribe Therapeutics in a report on Tuesday, August 18th. They set an “outperform” rating and a $37.00 price objective for the company. Wells Fargo & Company assumed coverage on Scribe Therapeutics in a research note on Tuesday, August 18th. They issued an “overweight” rating and a $60.00 price objective for the company. Finally, Wall Street Zen upgraded Scribe Therapeutics to a “hold” rating in a report on Saturday, August 1st. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $51.75.

Scribe Therapeutics Price Performance

Shares of NASDAQ:SCTX opened at $29.00 on Wednesday. Scribe Therapeutics has a twelve month low of $17.31 and a twelve month high of $39.60.

Insider Activity

In other news, CFO David Parrot acquired 2,666 shares of the firm’s stock in a transaction on Thursday, July 23rd. The stock was purchased at an average price of $15.00 per share, for a total transaction of $39,990.00. Following the purchase, the chief financial officer owned 1,333 shares in the company, valued at approximately $19,995. This represents a -200.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Behzad Aghazadeh purchased 7,905 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The shares were acquired at an average cost of $18.25 per share, with a total value of $144,266.25. Following the completion of the transaction, the director directly owned 3,088,888 shares of the company’s stock, valued at $56,372,206. The trade was a 0.26% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders acquired 3,727,237 shares of company stock valued at $56,291,746.

Scribe Therapeutics Company Profile

Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.